What is CytomX Therapeutics's other non-current liabilities?

CytomX Therapeutics (CTMX) reported other non-current liabilities of $4.41M in Q1 2026.

How has CytomX Therapeutics's other non-current liabilities changed year-over-year?

CytomX Therapeutics's other non-current liabilities increased by 5.6% year-over-year, from $4.18M to $4.41M.

What does other non-current liabilities mean?

Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.

CytomX Therapeutics CTMX Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

PfizerPFE

$14.2B+6.8%

AmgenAMGN

$2.37B+7.0%

Allogene TherapeuticsALLO

$16.12M+43.0%

Perspective TherapeuticsCATX

$437K+201%

Arcus BiosciencesRCUS

$119M-28.3%

Cogent Biosciences, Inc.COGT

$62K+1,140%

Other financials

Income statement

See full

Revenue$10.3M-79.9%

Operating income-$19.7M-187%

Net income-$18.2M-178%

EPS (diluted)-$0.10-137%

Balance sheet

See full

Cash & equivalents$28.8M-39.4%

Total debt$2.9M-65.0%

Total equity$319.9M+1,177%

Total assets$359.4M+265%

Cash flow

See full

Operating cash flow-$25.5M-21.4%

CapEx--100%

Free cash flow-$25.5M-20.7%

Valuation

See full

Market cap$711.89M+94.8%

Enterprise value$685.92M+110%

P/S20×+17.6×

Profitability

See full

Operating margin-181.9%-206pp

Net margin-166.4%-195pp

FCF margin-225.6%-334pp

Returns & leverage

See full

Return on equity-34.3%—

Debt / equity0×-0.3×

Current ratio10.4×+8.7×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CytomX Therapeutics's other non-current liabilities?: CytomX Therapeutics (CTMX) reported other non-current liabilities of $4.41M in Q1 2026.
How has CytomX Therapeutics's other non-current liabilities changed year-over-year?: CytomX Therapeutics's other non-current liabilities increased by 5.6% year-over-year, from $4.18M to $4.41M.
What does other non-current liabilities mean?: Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.